WALD
Company Description
Waldencast Acquisition Corp. a skin care company, provides advanced skin care treatments. Its products are designed to help minimize the appearance of premature skin aging, skin damage, hyperpigmentation, acne, and sun damage primarily available through dermatologists, plastic surgeons, medical spas, and other skin care professionals. Its portfolio includes Obagi Medical that provides transformational skin care products formulated to minimize signs of skin aging, address dark spots, hyperpigmentation, fine lines, and wrinkles and to protect and enhance skin tone and texture; and Obagi Clinical that offers skin care products designed to prevent the early signs of skin aging. The company was founded in 1988 and is based in White Plains, New York.
Track Record
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Revenue | 272.07M | 273.87M | 218.14M | 166.13M | 142.47M | 94.43M |
| Net Income | (229.75M) | (42.44M) | (89.98M) | (116.62M) | (19.58M) | (2.37M) |
| EPS | -2.01 | -0.39 | -0.89 | -1.08 | -0.45 | -0.20 |
| Free Cash Flow | (16.25M) | (11.83M) | (31.82M) | (87.51M) | 2.24M | (9.14M) |
| FCF / Share | -0.14 | -0.11 | -0.31 | -0.81 | 0.05 | -0.78 |
| Operating CF | (12.82M) | (8.82M) | (29.77M) | (85.01M) | 3.53M | (7.43M) |
| Total Assets | 816.20M | 975.86M | 1.04B | 1.09B | 184.59M | 166,792 |
| Total Debt | 149.01M | 182.11M | 177.72M | 199.25M | 118.86M | 0 |
| Cash & Equiv | 31.89M | 14.80M | 22.58M | 8.69M | 12.79M | 0 |
| Book Value | 461.88M | 662.32M | 624.63M | 639.24M | 39.24M | (10,951) |
| Return on Equity | -0.50 | -0.06 | -0.14 | -0.18 | -0.50 | N/A |
| Metric | Q4 2025 | Q2 2025 | Q4 2024 | Q2 2024 | Q4 2023 | Q2 2023 | Q4 2022 | Q2 2022 | Q4 2021 | Q2 2021 | Q4 2020 | Q2 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 139.80M | 132.27M | 142.29M | 131.58M | 108.80M | 109.34M | 89.85M | 76.28M | 71.24M | 71.24M | 47.21M | 47.21M |
| Net Income | (60.31M) | (169.44M) | (32.37M) | (10.07M) | (78.21M) | (11.77M) | (107.15M) | (9.47M) | (9.79M) | (9.79M) | (1.19M) | (1.19M) |
| EPS | -0.51 | -1.51 | -0.29 | -0.09 | -0.64 | -0.11 | -1.00 | -0.08 | -0.23 | -0.23 | -0.10 | -0.10 |
| Free Cash Flow | (2.15M) | (14.10M) | 1.14M | (12.67M) | (13.86M) | (17.51M) | (43.76M) | (43.76M) | 352,628 | 1.12M | (4.57M) | (4.57M) |
| FCF / Share | -0.02 | -0.13 | 0.01 | -0.11 | -0.11 | -0.16 | -0.41 | -0.41 | 0.01 | 0.03 | -0.39 | -0.39 |
| Operating CF | (1.29M) | (11.53M) | 2.56M | (11.38M) | (13.41M) | (16.36M) | (42.51M) | (42.51M) | 352,628 | 1.76M | (3.72M) | (3.72M) |
| Total Assets | 816.20M | 797.75M | 975.86M | 1.01B | 1.04B | 1.09B | 1.09B | N/A | 184.59M | 346.30M | 200,731 | N/A |
| Total Debt | 149.01M | 193.08M | 182.11M | 188.49M | 177.72M | 229.93M | 199.25M | N/A | 118.86M | 0 | 0 | N/A |
| Cash & Equiv | 31.89M | 10.48M | 14.80M | 19.69M | 22.58M | 18.90M | 8.69M | N/A | 12.79M | 851,860 | 0 | N/A |
| Book Value | 461.88M | 499.14M | 662.32M | 618.61M | 624.63M | 615.28M | 639.24M | N/A | 39.24M | 301.88M | 14,049 | N/A |
| Return on Equity | -0.13 | -0.34 | -0.05 | -0.02 | -0.13 | -0.02 | -0.17 | N/A | -0.25 | -0.03 | -84.35 | N/A |
